CVRx Q1 revenue $14.8M (+20% YoY); raises FY gross margin guidance

CVRx, Inc.

2026-Q1 EPS reported -$0.50 vs consensus -$0.51 ▲ beat (+2.8%)

U.S. revenue $13.7M (+22% YoY); active implanting centers grew to 257 from 227 a year ago.
Net loss $13.1M ($0.50 EPS) vs $13.8M ($0.53 EPS) in Q1 2025.
First site activated and first patient enrolled in BENEFIT-HF trial; could expand indicated population ~3x.
FY2026 guidance: revenue $63-67M; gross margin raised to 85-87% from prior 84-86%.
Cash $72.3M; Q2 2026 revenue expected $15.1-16.1M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CVRx, Inc. reported first quarter ended March 31, 2026 results: revenue $14.8 million, net income $13.1 million, or $0.50 per share, EPS $0.50 per share. Guidance reaffirmed.

Period: first quarter ended March 31, 2026
Revenue: $14.8 million
Net income: $13.1 million, or $0.50 per share
EPS: $0.50 per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

cardiovascular diseases, today announced its financial and operating results for the first quarter of 2026. Recent Highlights · Total revenue for the first quarter of 2026 was $14.8 million, an increase of approximately 20% over the prior year quarter · U.S. revenue for the first quarter of 2026 was $13.7 million, an increase of 22% over the prior year quarter ·

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

CVRx, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-058655

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.